Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLKNASDAQ:MRNSOTCMKTS:NRIFFOTCMKTS:SOAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.20 million shsN/AMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.82 million shs260 shsNRIFFNuvo Pharmaceuticals$0.00$0.30▼$0.87$8.52M1.577,337 shs3,000 shsSOANAngioSoma$0.00$0.00▼$0.09$32.57M-0.466.74 million shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+43.02%-68.95%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-56.42%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SOANAngioSoma0.00%0.00%0.00%0.00%-81.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos2.7918 of 5 stars3.10.00.04.70.02.51.3MRNSMarinus Pharmaceuticals2.2558 of 5 stars3.20.00.04.20.61.70.6NRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.25Hold$2.00507.72% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideNRIFFNuvo Pharmaceuticals 0.00N/AN/AN/ASOANAngioSoma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77NRIFFNuvo Pharmaceuticals$52.41M0.00N/A0.82$1.59 per share0.00SOANAngioSomaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)NRIFFNuvo Pharmaceuticals$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/ASOANAngioSoma-$540KN/A0.00N/AN/AN/AN/A-1,245.34%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08MRNSMarinus PharmaceuticalsN/A1.661.47NRIFFNuvo Pharmaceuticals5.272.672.11SOANAngioSomaN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%MRNSMarinus Pharmaceuticals98.80%NRIFFNuvo PharmaceuticalsN/ASOANAngioSoma0.02%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%MRNSMarinus Pharmaceuticals5.46%NRIFFNuvo PharmaceuticalsN/ASOANAngioSomaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableNRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionableSOANAngioSomaN/A476.83 millionN/ANot OptionableNRIFF, SOAN, MRNS, and ALLK HeadlinesRecent News About These CompaniesWatch: Unhygienic Making Process Of Soan Papdi Goes Viral, Leaves Internet DisgustedNovember 7, 2024 | food.ndtv.comFNational Security Adviser and Joint Chiefs Chair at U.S. Global Leadership ForumSeptember 19, 2024 | c-span.orgCC-SPAN TV ScheduleAugust 21, 2024 | c-span.orgCC-SPAN Radio ScheduleJuly 31, 2024 | c-span.orgCC-SPAN 2 TV ScheduleJuly 29, 2024 | c-span.orgCQ&A with Riley GainesJuly 19, 2024 | c-span.orgCSenate SessionApril 28, 2024 | c-span.orgCMartin SoanApril 22, 2024 | chortle.co.ukCDeath Clock / Life Span ClockApril 17, 2024 | medindia.netMWisconsin for KennedyApril 16, 2024 | c-span.orgCSinking of TitanicApril 1, 2024 | c-span.orgCSenator Laphonza Butler on Book BansMarch 29, 2024 | c-span.orgCAttention Span TestMarch 25, 2024 | psychologytoday.comPJane MarieMarch 17, 2024 | c-span.orgCThe ShowmanMarch 11, 2024 | c-span.orgCSuper Tuesday Primary ResultsMarch 6, 2024 | c-span.orgCSouth Carolina Republican Primary CoverageFebruary 25, 2024 | c-span.orgCGateway to StatesmanshipFebruary 25, 2024 | c-span.orgCAbout Books with Daniel PaisnerFebruary 23, 2024 | c-span.orgCLectures in History VideosFebruary 19, 2024 | c-span.orgCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIFF, SOAN, MRNS, and ALLK Company DescriptionsAllakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Nuvo Pharmaceuticals OTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.AngioSoma OTCMKTS:SOANAngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
